Monoclonal antibody therapies against anthrax.
Monoclonal antibody therapies against anthrax.
复制标题
抗炭疽的单克隆抗体疗法。
DOI：
10.3390/toxins3081004
复制
发表时间：
2011-08
期刊：
影响因子：
4.2
通讯作者：
Purcell R
中科院分区：
文献类型：
--
作者：
Chen Z;Moayeri M;Purcell R
炭疽病是一种高度致命的传染病，由孢子形成细菌炭疽杆菌引起。它不仅引起人类的自然感染，而且作为一种新兴的生物恐怖制剂构成了巨大的威胁。炭疽的致命性主要归因于两个主要的毒力因子：毒素和荚膜。已经进行了广泛的努力来产生治疗上有用的单克隆抗体的毒力成分：保护性抗原（PA），致死因子（LF）和水肿因子（EF），和胶囊的B。炭疽病本文综述了抗炭疽单克隆抗体的发展现状，并认为识别不同表位或不同毒力因子的单克隆抗体混合物具有潜在的治疗优势。
Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.